WuXi AppTec Co., Ltd. (HKG:2359)

Market Cap	210.44B
Revenue (ttm)	42.65B
Net Income (ttm)	8.93B
Shares Out	n/a
EPS (ttm)	3.04
PE Ratio	23.56
Forward PE	n/a
Dividend	1.09 (1.55%)
Ex-Dividend Date	Jun 17, 2024

Volume	17,841,621
Average Volume	6,056,964
Open	66.80
Previous Close	66.15
Day's Range	65.50 - 71.00
52-Week Range	27.50 - 72.45
Beta	0.84
RSI	77.53
Earnings Date	Mar 18, 2025

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs and advanced therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates in six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 41,116
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2359

Financial Performance

In 2023, WuXi AppTec's revenue was 40.34 billion, an increase of 2.51% compared to the previous year's 39.35 billion. Earnings were 9.61 billion, an increase of 9.00%.

Financial numbers in CNY